Peripartum cardiomyopathy (PPCM) is a rare but serious form of heart failure that occurs during the last month of pregnancy or up to five months postpartum.
This condition is characterized by the weakening of the heart muscle, leading to a reduced ejection fraction and, subsequently, heart failure symptoms.
While PPCM can affect women of all ethnicities, recent studies have indicated a higher prevalence and more severe outcomes among African women, particularly in Nigeria.
This article aims to explore the risk factors, clinical outcomes, and current understanding of PPCM among Nigerian women, with a focus on raising awareness and driving further research into this critical health issue.
Epidemiology and Risk Factors
PPCM is a global health concern, but its incidence is notably higher in African countries compared to Western nations.
A study conducted in Nigeria reported an incidence rate of 1 in 100 deliveries, which is significantly higher than the global average of 1 in 2,000 to 4,000 deliveries (Isezuo & Abubakar, 2007).
The reasons for this elevated incidence are multifaceted, involving genetic, environmental, and socio-economic factors.
Genetic predisposition plays a crucial role in the development of PPCM. Research has identified several genetic mutations linked to PPCM, many of which are more prevalent among individuals of African descent (Ware et al., 2016).
These mutations may lead to a higher susceptibility to heart muscle damage during the peripartum period.
Additionally, the presence of co-morbid conditions such as hypertension, diabetes, and obesity, which are prevalent in Nigeria, further exacerbates the risk of developing PPCM (Karaye et al., 2014).
Another significant risk factor is the delayed access to and utilization of antenatal care services in Nigeria.
Due to various socio-economic challenges, many Nigerian women do not receive adequate prenatal care, leading to the late detection of PPCM and other pregnancy-related complications (Sliwa et al., 2010).
Furthermore, cultural practices and misconceptions about pregnancy-related health issues contribute to the underreporting and mismanagement of PPCM in Nigeria.
Clinical Presentation and Diagnosis
The clinical presentation of PPCM can be subtle and is often mistaken for normal pregnancy-related symptoms such as fatigue, shortness of breath, and swelling in the lower extremities.
However, these symptoms can rapidly progress to severe heart failure if not promptly recognized and treated.
Nigerian women with PPCM often present with more advanced disease due to delays in seeking medical attention and the lack of awareness among healthcare providers (Mebazaa et al., 2014).
Diagnosis of PPCM relies on the exclusion of other causes of heart failure and the presence of a reduced ejection fraction (less than 45%) on echocardiography (Sliwa et al., 2010).
In Nigeria, the availability of advanced diagnostic tools such as echocardiography is limited, particularly in rural areas, leading to underdiagnosis and delayed treatment.
This diagnostic challenge is compounded by the overlap of PPCM symptoms with those of endemic diseases such as malaria and anemia, which are common in Nigerian women.
Management and Outcomes
The management of PPCM in Nigeria faces several obstacles, including limited access to healthcare facilities, lack of specialized care, and financial constraints.
Standard treatment for PPCM involves the use of heart failure medications such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and diuretics, alongside lifestyle modifications (Gheorghiade et al., 2006).
However, the availability of these medications and the ability to monitor their effects are often restricted in Nigerian healthcare settings.
Despite these challenges, there have been some positive outcomes reported in Nigerian women with PPCM, particularly with early diagnosis and appropriate management.
However, the overall prognosis remains poor compared to women in developed countries, with a higher rate of mortality and long-term complications (Karaye et al., 2014).
This disparity underscores the need for improved healthcare infrastructure, better access to diagnostic tools, and increased awareness of PPCM among healthcare providers and the general population in Nigeria.
Conclusion
Peripartum cardiomyopathy is a significant health concern for Nigerian women, with a higher incidence and worse outcomes compared to their counterparts in other regions.
The interplay of genetic factors, co-morbid conditions, and socio-economic challenges contributes to the burden of this disease in Nigeria.
Addressing PPCM in Nigeria requires a multifaceted approach, including improved access to antenatal care, increased awareness among healthcare providers, and the development of targeted interventions for early diagnosis and treatment.
By focusing on these areas, there is potential to reduce the incidence and improve the outcomes of PPCM among Nigerian women, ultimately contributing to better maternal health in the country.
References
Gheorghiade, M., Colucci, W. S., & Swedberg, K. (2006). Beta-blockers in chronic heart failure. Circulation, 113(4), 1020-1027.
Karaye, K. M., Henein, M. Y., & Mairami, Z. S. (2014). Clinical features and prognosis of peripartum cardiomyopathy in Nigerian women. International Journal of Cardiology, 176(3), 1213-1218.
Mebazaa, A., Seronde, M. F., Gayat, E., Chioncel, O., & Sliwa, K. (2014). New biomarkers for heart failure management in developing countries: Peripartum cardiomyopathy. International Journal of Cardiology, 172(3), 328-337.
Sliwa, K., Hilfiker-Kleiner, D., Petrie, M. C., Mebazaa, A., Pieske, B., & Buchmann, E. (2010). Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 12(8), 767-778.
Ware, J. S., Li, J., Mazaika, E., Yasso, C. M., & DePalma, S. R. (2016). Shared genetic predisposition in peripartum and dilated cardiomyopathies. New England Journal of Medicine, 374(3), 233-241.
